Login to Your Account

Still Jumping on IPO Bandwagon

Ultragenyx, Cara File; Uniqure Tips Hat to IPO

By Marie Powers
Staff Writer

Monday, November 11, 2013
Just two years after bursting onto the rare disease scene with a $45 million Series A, Ultragenyx Pharmaceutical Inc. filed an S-1 with the SEC seeking to raise up to $86.3 million in an initial public offering (IPO). Filing, like other biotechs, as an emerging growth company, the Novato, Calif.-based company applied to list on Nasdaq under the symbol “RARE.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription